 Andrew Goodwin
Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 11 | 2025 | 517 | 3.610 |
Why?
| | Silicon Dioxide | 8 | 2025 | 119 | 2.390 |
Why?
| | Microbubbles | 8 | 2019 | 53 | 2.030 |
Why?
| | Contrast Media | 9 | 2019 | 497 | 1.550 |
Why?
| | Prodrugs | 3 | 2022 | 52 | 1.440 |
Why?
| | Fluorocarbons | 4 | 2017 | 120 | 1.380 |
Why?
| | Nanostructures | 5 | 2025 | 105 | 1.320 |
Why?
| | High-Intensity Focused Ultrasound Ablation | 3 | 2019 | 13 | 1.310 |
Why?
| | Ultrasonography | 7 | 2017 | 785 | 1.290 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2021 | 133 | 1.230 |
Why?
| | Biosensing Techniques | 3 | 2015 | 142 | 1.170 |
Why?
| | Hydrogels | 5 | 2025 | 701 | 1.120 |
Why?
| | Ultrasonic Waves | 2 | 2025 | 9 | 1.080 |
Why?
| | Ultrasonic Therapy | 2 | 2018 | 16 | 1.060 |
Why?
| | Phospholipids | 2 | 2019 | 214 | 1.000 |
Why?
| | Cytosine Deaminase | 3 | 2022 | 15 | 0.950 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 4 | 2020 | 192 | 0.910 |
Why?
| | Gelatin | 1 | 2025 | 56 | 0.890 |
Why?
| | Antineoplastic Agents | 4 | 2025 | 2214 | 0.880 |
Why?
| | Flucytosine | 3 | 2022 | 10 | 0.840 |
Why?
| | Aptamers, Nucleotide | 3 | 2015 | 87 | 0.820 |
Why?
| | Acoustics | 3 | 2019 | 48 | 0.820 |
Why?
| | Thrombin | 3 | 2014 | 172 | 0.800 |
Why?
| | Gold | 3 | 2022 | 116 | 0.800 |
Why?
| | Phosphatidylethanolamines | 3 | 2014 | 76 | 0.780 |
Why?
| | Cross-Linking Reagents | 5 | 2024 | 206 | 0.770 |
Why?
| | Spheroids, Cellular | 4 | 2024 | 74 | 0.750 |
Why?
| | Fluorouracil | 2 | 2022 | 231 | 0.740 |
Why?
| | ErbB Receptors | 3 | 2021 | 635 | 0.730 |
Why?
| | Theranostic Nanomedicine | 2 | 2019 | 15 | 0.720 |
Why?
| | Protein Aggregates | 1 | 2021 | 84 | 0.650 |
Why?
| | Polyethylene Glycols | 4 | 2019 | 649 | 0.650 |
Why?
| | Acrylic Resins | 2 | 2018 | 46 | 0.630 |
Why?
| | DNA | 7 | 2024 | 1435 | 0.630 |
Why?
| | Drug Packaging | 1 | 2020 | 41 | 0.620 |
Why?
| | Cell Line, Tumor | 13 | 2025 | 3542 | 0.610 |
Why?
| | Nitroreductases | 1 | 2019 | 6 | 0.590 |
Why?
| | Embolism | 1 | 2019 | 48 | 0.590 |
Why?
| | Drug Delivery Systems | 4 | 2019 | 381 | 0.580 |
Why?
| | Thrombectomy | 1 | 2019 | 78 | 0.570 |
Why?
| | Osmosis | 1 | 2018 | 22 | 0.560 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2018 | 35 | 0.560 |
Why?
| | Dendrimers | 3 | 2025 | 21 | 0.540 |
Why?
| | Blood-Brain Barrier | 1 | 2019 | 160 | 0.520 |
Why?
| | Hydrogen Peroxide | 2 | 2018 | 335 | 0.500 |
Why?
| | Neoplasms | 5 | 2024 | 2906 | 0.470 |
Why?
| | Quinones | 1 | 2015 | 11 | 0.470 |
Why?
| | Drug Carriers | 4 | 2025 | 136 | 0.460 |
Why?
| | Thrombosis | 1 | 2019 | 400 | 0.450 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 981 | 0.450 |
Why?
| | Surface Properties | 3 | 2025 | 386 | 0.440 |
Why?
| | Particle Size | 4 | 2025 | 381 | 0.420 |
Why?
| | Nanotubes, Carbon | 3 | 2009 | 46 | 0.420 |
Why?
| | Membrane Proteins | 1 | 2020 | 1164 | 0.410 |
Why?
| | Blood Coagulation | 2 | 2013 | 274 | 0.410 |
Why?
| | Fluorescent Dyes | 1 | 2015 | 333 | 0.400 |
Why?
| | Breast Neoplasms | 5 | 2023 | 2382 | 0.400 |
Why?
| | Polyesters | 2 | 2019 | 75 | 0.390 |
Why?
| | Molecular Imaging | 1 | 2012 | 57 | 0.360 |
Why?
| | Blood | 1 | 2012 | 107 | 0.360 |
Why?
| | Venous Thrombosis | 1 | 2013 | 196 | 0.340 |
Why?
| | Micelles | 2 | 2009 | 39 | 0.300 |
Why?
| | Photochemical Processes | 2 | 2021 | 103 | 0.300 |
Why?
| | Adsorption | 2 | 2020 | 153 | 0.300 |
Why?
| | Rabbits | 4 | 2014 | 652 | 0.290 |
Why?
| | Stress, Mechanical | 2 | 2021 | 494 | 0.280 |
Why?
| | Animals | 18 | 2025 | 38030 | 0.280 |
Why?
| | Dextrans | 1 | 2009 | 84 | 0.280 |
Why?
| | Coated Materials, Biocompatible | 1 | 2009 | 65 | 0.280 |
Why?
| | Metal Nanoparticles | 1 | 2009 | 80 | 0.270 |
Why?
| | Recombinant Fusion Proteins | 2 | 2021 | 666 | 0.270 |
Why?
| | Propionates | 1 | 2007 | 39 | 0.250 |
Why?
| | Drug Liberation | 2 | 2025 | 36 | 0.240 |
Why?
| | Cattle | 2 | 2019 | 946 | 0.240 |
Why?
| | Volatilization | 2 | 2017 | 45 | 0.240 |
Why?
| | Platelet Factor 4 | 1 | 2026 | 36 | 0.240 |
Why?
| | Streptavidin | 2 | 2015 | 15 | 0.230 |
Why?
| | Caco-2 Cells | 2 | 2022 | 79 | 0.230 |
Why?
| | Infrared Rays | 1 | 2005 | 24 | 0.230 |
Why?
| | Spectrometry, Fluorescence | 3 | 2021 | 165 | 0.220 |
Why?
| | Solutions | 2 | 2015 | 159 | 0.220 |
Why?
| | Heparin | 1 | 2026 | 247 | 0.210 |
Why?
| | Thrombocytopenia | 1 | 2026 | 204 | 0.210 |
Why?
| | Nanotubes | 2 | 2018 | 46 | 0.210 |
Why?
| | Mice | 10 | 2025 | 18329 | 0.200 |
Why?
| | EGF Family of Proteins | 1 | 2022 | 17 | 0.190 |
Why?
| | Humans | 26 | 2026 | 145474 | 0.190 |
Why?
| | Cell Adhesion | 2 | 2021 | 451 | 0.180 |
Why?
| | Autoantibodies | 2 | 2026 | 1509 | 0.180 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2025 | 258 | 0.180 |
Why?
| | Primates | 1 | 2022 | 133 | 0.180 |
Why?
| | Scattering, Radiation | 2 | 2011 | 98 | 0.170 |
Why?
| | Mice, Nude | 1 | 2022 | 679 | 0.160 |
Why?
| | Anticoagulants | 1 | 2026 | 748 | 0.160 |
Why?
| | Amyloid | 1 | 2021 | 94 | 0.160 |
Why?
| | Cell Death | 1 | 2021 | 382 | 0.150 |
Why?
| | Cell Communication | 1 | 2021 | 328 | 0.150 |
Why?
| | Protein Denaturation | 1 | 2019 | 76 | 0.150 |
Why?
| | Glass | 1 | 2019 | 46 | 0.150 |
Why?
| | Enzymes, Immobilized | 1 | 2019 | 30 | 0.140 |
Why?
| | Permeability | 1 | 2019 | 169 | 0.140 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2019 | 179 | 0.130 |
Why?
| | Pressure | 1 | 2018 | 226 | 0.130 |
Why?
| | Phantoms, Imaging | 1 | 2018 | 159 | 0.130 |
Why?
| | Metal-Organic Frameworks | 1 | 2017 | 3 | 0.130 |
Why?
| | DNA, Satellite | 1 | 2017 | 18 | 0.130 |
Why?
| | Escherichia coli Proteins | 1 | 2019 | 201 | 0.130 |
Why?
| | Photochemotherapy | 1 | 2017 | 39 | 0.130 |
Why?
| | Cell Membrane | 1 | 2020 | 707 | 0.120 |
Why?
| | Photosensitizing Agents | 1 | 2017 | 42 | 0.120 |
Why?
| | Analgesics, Opioid | 1 | 2025 | 1149 | 0.120 |
Why?
| | Doxorubicin | 3 | 2019 | 401 | 0.120 |
Why?
| | Poloxamer | 1 | 2016 | 10 | 0.120 |
Why?
| | Photons | 2 | 2007 | 67 | 0.120 |
Why?
| | Air | 1 | 2016 | 44 | 0.120 |
Why?
| | Protein Conformation | 1 | 2019 | 938 | 0.120 |
Why?
| | Cell Movement | 1 | 2020 | 959 | 0.120 |
Why?
| | Biotinylation | 1 | 2015 | 37 | 0.120 |
Why?
| | Ultraviolet Rays | 1 | 2018 | 384 | 0.110 |
Why?
| | Hot Temperature | 1 | 2018 | 396 | 0.110 |
Why?
| | Tumor Microenvironment | 3 | 2024 | 734 | 0.110 |
Why?
| | Biotin | 1 | 2015 | 32 | 0.110 |
Why?
| | Ultrasonics | 1 | 2015 | 50 | 0.110 |
Why?
| | Gases | 1 | 2014 | 46 | 0.100 |
Why?
| | Female | 11 | 2026 | 78844 | 0.100 |
Why?
| | Pathology, Clinical | 1 | 2014 | 29 | 0.100 |
Why?
| | Microscopy, Fluorescence | 1 | 2015 | 408 | 0.100 |
Why?
| | Temperature | 1 | 2017 | 633 | 0.100 |
Why?
| | Nanotechnology | 1 | 2014 | 114 | 0.100 |
Why?
| | United States Food and Drug Administration | 2 | 2025 | 208 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2015 | 552 | 0.100 |
Why?
| | Cell Proliferation | 1 | 2020 | 2507 | 0.100 |
Why?
| | Diagnostic Errors | 1 | 2014 | 178 | 0.090 |
Why?
| | Erythrocytes | 1 | 2018 | 748 | 0.090 |
Why?
| | Polymers | 2 | 2007 | 485 | 0.090 |
Why?
| | 1,2-Dipalmitoylphosphatidylcholine | 1 | 2011 | 11 | 0.090 |
Why?
| | Light | 2 | 2011 | 403 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 337 | 0.090 |
Why?
| | Phenylpropionates | 1 | 2011 | 27 | 0.090 |
Why?
| | Water | 1 | 2014 | 445 | 0.080 |
Why?
| | Oligonucleotides | 1 | 2011 | 153 | 0.080 |
Why?
| | Insulin | 1 | 2021 | 2512 | 0.080 |
Why?
| | Base Sequence | 1 | 2013 | 2170 | 0.080 |
Why?
| | Ferrosoferric Oxide | 1 | 2009 | 25 | 0.080 |
Why?
| | Protein Binding | 1 | 2015 | 2238 | 0.070 |
Why?
| | Lipids | 1 | 2014 | 707 | 0.070 |
Why?
| | Naphthoquinones | 2 | 2007 | 20 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1963 | 0.070 |
Why?
| | Luminescent Measurements | 1 | 2009 | 75 | 0.070 |
Why?
| | Spectrum Analysis, Raman | 1 | 2008 | 37 | 0.070 |
Why?
| | Protein Array Analysis | 1 | 2008 | 56 | 0.070 |
Why?
| | Image Enhancement | 1 | 2009 | 200 | 0.070 |
Why?
| | Microvessels | 1 | 2009 | 97 | 0.070 |
Why?
| | Oxidoreductases Acting on CH-NH Group Donors | 1 | 2008 | 3 | 0.070 |
Why?
| | Drug Stability | 1 | 2009 | 169 | 0.070 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2008 | 47 | 0.070 |
Why?
| | Carbon | 1 | 2009 | 176 | 0.070 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2009 | 140 | 0.070 |
Why?
| | Magnetic Resonance Angiography | 1 | 2009 | 251 | 0.070 |
Why?
| | Pargyline | 1 | 2007 | 3 | 0.070 |
Why?
| | Hydroxy Acids | 1 | 2007 | 4 | 0.070 |
Why?
| | Propylamines | 1 | 2007 | 11 | 0.060 |
Why?
| | Cyclization | 1 | 2007 | 22 | 0.060 |
Why?
| | Benzylamines | 1 | 2007 | 44 | 0.060 |
Why?
| | Signal Transduction | 1 | 2020 | 5216 | 0.060 |
Why?
| | Polyelectrolytes | 1 | 2026 | 15 | 0.060 |
Why?
| | Receptors, IgG | 1 | 2026 | 77 | 0.060 |
Why?
| | Platelet Activation | 1 | 2026 | 99 | 0.060 |
Why?
| | Oxazines | 1 | 2005 | 37 | 0.060 |
Why?
| | Pharmacoepidemiology | 1 | 2025 | 23 | 0.060 |
Why?
| | Drug Labeling | 1 | 2025 | 37 | 0.060 |
Why?
| | Chitosan | 1 | 2025 | 39 | 0.050 |
Why?
| | Acetals | 1 | 2004 | 3 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2008 | 588 | 0.050 |
Why?
| | Time Factors | 1 | 2015 | 7123 | 0.050 |
Why?
| | Surface-Active Agents | 1 | 2005 | 98 | 0.050 |
Why?
| | Lysosomes | 1 | 2005 | 131 | 0.050 |
Why?
| | Methotrexate | 1 | 2025 | 233 | 0.050 |
Why?
| | Deoxycytidine | 1 | 2025 | 220 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2026 | 848 | 0.050 |
Why?
| | Biomarkers | 1 | 2015 | 4295 | 0.050 |
Why?
| | Antigen Presentation | 1 | 2005 | 207 | 0.050 |
Why?
| | Cell Hypoxia | 1 | 2024 | 247 | 0.050 |
Why?
| | Blood Platelets | 1 | 2026 | 379 | 0.050 |
Why?
| | Coculture Techniques | 1 | 2023 | 247 | 0.050 |
Why?
| | Cadherins | 1 | 2023 | 200 | 0.040 |
Why?
| | Molecular Structure | 3 | 2009 | 486 | 0.040 |
Why?
| | Reactive Oxygen Species | 2 | 2018 | 611 | 0.040 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2021 | 156 | 0.040 |
Why?
| | Cell Survival | 2 | 2017 | 1100 | 0.040 |
Why?
| | Cell Cycle | 1 | 2021 | 598 | 0.030 |
Why?
| | Titanium | 1 | 2018 | 74 | 0.030 |
Why?
| | Singlet Oxygen | 1 | 2017 | 18 | 0.030 |
Why?
| | Opioid-Related Disorders | 1 | 2025 | 602 | 0.030 |
Why?
| | United States | 2 | 2025 | 16098 | 0.030 |
Why?
| | New Hampshire | 1 | 2014 | 11 | 0.030 |
Why?
| | Vermont | 1 | 2014 | 13 | 0.030 |
Why?
| | Expert Testimony | 1 | 2014 | 42 | 0.030 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 61 | 0.030 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2014 | 89 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2005 | 531 | 0.020 |
Why?
| | Pregnancy | 1 | 2025 | 7202 | 0.020 |
Why?
| | Fourier Analysis | 1 | 2011 | 42 | 0.020 |
Why?
| | Aged | 2 | 2026 | 26153 | 0.020 |
Why?
| | Nonlinear Dynamics | 1 | 2011 | 92 | 0.020 |
Why?
| | Graphite | 1 | 2009 | 14 | 0.020 |
Why?
| | Cobalt | 1 | 2009 | 50 | 0.020 |
Why?
| | Blood Circulation Time | 1 | 2009 | 3 | 0.020 |
Why?
| | Myeloblastin | 1 | 2008 | 8 | 0.020 |
Why?
| | Carbon Radioisotopes | 1 | 2008 | 29 | 0.020 |
Why?
| | Middle Aged | 2 | 2026 | 36215 | 0.020 |
Why?
| | Solubility | 1 | 2009 | 240 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2009 | 246 | 0.020 |
Why?
| | Carbon Isotopes | 1 | 2008 | 143 | 0.020 |
Why?
| | Polyamines | 1 | 2008 | 42 | 0.020 |
Why?
| | Mice, SCID | 1 | 2009 | 369 | 0.020 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2008 | 112 | 0.020 |
Why?
| | Spectrophotometry, Infrared | 1 | 2007 | 53 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2008 | 387 | 0.020 |
Why?
| | Azo Compounds | 1 | 2007 | 30 | 0.020 |
Why?
| | Materials Testing | 1 | 2009 | 345 | 0.020 |
Why?
| | Drug Design | 1 | 2008 | 175 | 0.020 |
Why?
| | Models, Chemical | 1 | 2008 | 250 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2008 | 397 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2008 | 247 | 0.010 |
Why?
| | Models, Genetic | 1 | 2008 | 524 | 0.010 |
Why?
| | Registries | 1 | 2014 | 2406 | 0.010 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2005 | 39 | 0.010 |
Why?
| | DNA Damage | 1 | 2008 | 437 | 0.010 |
Why?
| | Child | 1 | 2025 | 22707 | 0.010 |
Why?
| | Biocompatible Materials | 1 | 2009 | 429 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 2005 | 159 | 0.010 |
Why?
| | Hydrolysis | 1 | 2005 | 197 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2005 | 396 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2005 | 177 | 0.010 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2005 | 202 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 2009 | 675 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2823 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2005 | 499 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2005 | 1132 | 0.010 |
Why?
| | Vaccines | 1 | 2005 | 388 | 0.010 |
Why?
| | Male | 2 | 2026 | 72842 | 0.010 |
Why?
| | Adult | 1 | 2014 | 40777 | 0.010 |
Why?
| | Glutethimide | 1 | 1969 | 4 | 0.000 |
Why?
| | Pituitary-Adrenal System | 1 | 1969 | 164 | 0.000 |
Why?
| | Adrenal Glands | 1 | 1969 | 76 | 0.000 |
Why?
| | Adrenocorticotropic Hormone | 1 | 1969 | 147 | 0.000 |
Why?
| | Pituitary Gland | 1 | 1969 | 149 | 0.000 |
Why?
| | Stress, Physiological | 1 | 1969 | 443 | 0.000 |
Why?
| | Rats | 1 | 1969 | 5584 | 0.000 |
Why?
|
|
Goodwin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|